|
EP2251341A1
(en)
*
|
2005-07-14 |
2010-11-17 |
Astellas Pharma Inc. |
Heterocyclic Janus kinase 3 inhibitors
|
|
KR20080026654A
(ko)
|
2005-07-14 |
2008-03-25 |
아스텔라스세이야쿠 가부시키가이샤 |
헤테로시클릭 야누스 키나제 3 억제제
|
|
KR101391900B1
(ko)
|
2005-12-13 |
2014-05-02 |
인사이트 코포레이션 |
야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
|
|
CN101578257A
(zh)
|
2006-11-02 |
2009-11-11 |
盐野义制药株式会社 |
羟基金刚烷胺的制造方法
|
|
JP5287253B2
(ja)
*
|
2007-01-12 |
2013-09-11 |
アステラス製薬株式会社 |
縮合ピリジン化合物
|
|
WO2008157208A2
(en)
|
2007-06-13 |
2008-12-24 |
Incyte Corporation |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
|
EP2175858B1
(en)
*
|
2007-07-11 |
2014-09-10 |
Pfizer Inc. |
Pharmaceutical compositions and methods of treating dry eye disorders
|
|
SI2074120T1
(sl)
*
|
2007-10-25 |
2010-06-30 |
Exelixis Inc |
Tropan spojine
|
|
HUE028347T2
(en)
*
|
2008-06-10 |
2016-12-28 |
Abbvie Inc |
Tricyclic compounds
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
|
JPWO2010058846A1
(ja)
*
|
2008-11-21 |
2012-04-19 |
アステラス製薬株式会社 |
４，６−ジアミノニコチンアミド化合物
|
|
EA021367B1
(ru)
*
|
2008-11-28 |
2015-06-30 |
Кова Компани, Лтд. |
Производное пиридин-3-карбоксамида
|
|
DK2432472T3
(da)
|
2009-05-22 |
2019-11-18 |
Incyte Holdings Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
|
|
TW201100429A
(en)
|
2009-05-22 |
2011-01-01 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
CA2764885C
(en)
|
2009-06-08 |
2018-05-15 |
Takeda Pharmaceutical Company Limited |
Dihydropyrrolonaphtyridinone compounds as inhibitors of jak
|
|
US9346809B2
(en)
|
2009-07-08 |
2016-05-24 |
Leo Pharma A/S |
Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors
|
|
FR2948369B1
(fr)
|
2009-07-27 |
2013-04-12 |
Sanofi Aventis |
Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
|
|
FR2948370B1
(fr)
|
2009-07-27 |
2013-04-05 |
Sanofi Aventis |
Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique
|
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
EP2488524B1
(en)
|
2009-10-15 |
2013-07-03 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine compounds
|
|
HUE033099T2
(en)
*
|
2009-12-01 |
2017-11-28 |
Abbvie Inc |
Novel tricyclic compounds
|
|
WO2011068899A1
(en)
*
|
2009-12-01 |
2011-06-09 |
Abbott Laboratories |
Novel tricyclic compounds
|
|
JP5739446B2
(ja)
|
2009-12-18 |
2015-06-24 |
ファイザー・インク |
ピロロ［２，３−ｄ］ピリミジン化合物
|
|
KR20140015162A
(ko)
*
|
2010-01-12 |
2014-02-06 |
에프. 호프만-라 로슈 아게 |
트라이사이클릭 헤테로사이클릭 화합물, 조성물 및 이의 사용 방법
|
|
PH12015502575A1
(en)
|
2010-03-10 |
2017-04-24 |
Incyte Corp |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
US8518945B2
(en)
|
2010-03-22 |
2013-08-27 |
Hoffmann-La Roche Inc. |
Pyrrolopyrazine kinase inhibitors
|
|
US8481541B2
(en)
|
2010-03-22 |
2013-07-09 |
Hoffmann-La Roche Inc. |
Pyrrolopyrazine kinase inhibitors
|
|
EP2571881A1
(en)
|
2010-05-20 |
2013-03-27 |
F.Hoffmann-La Roche Ag |
Pyrrolopyrazine derivatives as syk and jak inhibitors
|
|
EP3087972A1
(en)
|
2010-05-21 |
2016-11-02 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
|
EP2592080B1
(en)
*
|
2010-06-23 |
2016-02-24 |
Astellas Pharma Inc. |
Crystal of fused pyridine compound salt
|
|
US9198911B2
(en)
|
2010-11-02 |
2015-12-01 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
CA2818545C
(en)
|
2010-11-19 |
2019-04-16 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
CN103415515B
(zh)
|
2010-11-19 |
2015-08-26 |
因塞特公司 |
作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
|
|
CN103298817A
(zh)
*
|
2011-01-07 |
2013-09-11 |
利奥制药有限公司 |
作为蛋白酪氨酸激酶抑制剂的新磺酰胺哌嗪衍生物及其药物用途
|
|
PL2675451T3
(pl)
|
2011-02-18 |
2016-05-31 |
Novartis Pharma Ag |
Terapia skojarzona z inhibitorem mTOR/JAK
|
|
WO2012127506A1
(en)
|
2011-03-22 |
2012-09-27 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
|
US8691807B2
(en)
|
2011-06-20 |
2014-04-08 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
|
WO2013023119A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
JAK P13K/mTOR COMBINATION THERAPY
|
|
AU2012295802B2
(en)
*
|
2011-08-12 |
2017-03-30 |
Nissan Chemical Industries, Ltd. |
Tricyclic heterocyclic compounds and JAK inhibitors
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
SMT201800497T1
(it)
*
|
2011-12-21 |
2018-11-09 |
Shanghai hengrui pharmaceutical co ltd |
Derivato di pirrolo ad anello eteroarilico a sei elementi, relativo metodo di preparazione, e relativi usi medicinali
|
|
ES2567552T3
(es)
*
|
2012-01-30 |
2016-04-25 |
Cephalon, Inc. |
Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
|
|
UY34615A
(es)
*
|
2012-02-10 |
2013-09-30 |
Galapagos Nv |
Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
|
|
WO2013117649A1
(en)
*
|
2012-02-10 |
2013-08-15 |
Galapagos Nv |
Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
|
|
WO2013147135A1
(ja)
*
|
2012-03-30 |
2013-10-03 |
アステラス製薬株式会社 |
放出制御医薬組成物
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
GB201211021D0
(en)
*
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
|
WO2014043257A1
(en)
|
2012-09-12 |
2014-03-20 |
Rigel Pharmaceuticals, Inc. |
Treatment for vitiligo
|
|
JP2015529242A
(ja)
|
2012-09-21 |
2015-10-05 |
アドヴィヌス セラピューティクス リミテッドＡｄｖｉｎｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ |
置換された縮合三環式化合物、組成物およびその医薬用途
|
|
EP3949953A1
(en)
|
2012-11-15 |
2022-02-09 |
Incyte Holdings Corporation |
Sustained-release dosage forms of ruxolitinib
|
|
TW201513861A
(zh)
*
|
2013-01-17 |
2015-04-16 |
Galapagos Nv |
用於治療退化性及發炎疾病之新穎化合物
|
|
ES2755130T3
(es)
|
2013-02-08 |
2020-04-21 |
Nissan Chemical Corp |
Compuesto de pirrolopiridina tricíclico, e inhibidor de JAK
|
|
BR112015021458B1
(pt)
|
2013-03-06 |
2022-06-07 |
Incyte Holdings Corporation |
"processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
|
|
WO2014146246A1
(en)
*
|
2013-03-19 |
2014-09-25 |
Merck Sharp & Dohme Corp. |
Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
|
|
US9408835B2
(en)
|
2013-03-29 |
2016-08-09 |
Astellas Pharma Inc. |
Pharmaceutical composition for oral administration
|
|
WO2015021153A1
(en)
|
2013-08-07 |
2015-02-12 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
|
KR101548492B1
(ko)
|
2013-09-23 |
2015-09-01 |
건국대학교 산학협력단 |
야누스 키나아제 1 (Janus kinase 1)의 활성을 선택적으로 저해하는 4-아미노-7-아자인돌-5-카르복사마이드 유도체
|
|
NZ720092A
(en)
|
2013-12-05 |
2019-05-31 |
Pfizer |
Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
|
|
EP3653627A1
(en)
*
|
2014-04-22 |
2020-05-20 |
ArQule, Inc. |
Polymorphs of a substituted imidazopyridinyl-aminopyridine compound
|
|
ES2744213T3
(es)
|
2014-05-14 |
2020-02-24 |
Nissan Chemical Corp |
Compuesto tricíclico e inhibidor de JAK
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
WO2016047678A1
(ja)
*
|
2014-09-25 |
2016-03-31 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2017015267A1
(en)
*
|
2015-07-20 |
2017-01-26 |
Genzyme Corporation |
Colony stimulating factor-1 receptor (csf-1r) inhibitors
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
CA3251507A1
(en)
|
2015-10-16 |
2025-05-21 |
Abbvie Inc |
Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
|
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
|
US10730871B2
(en)
*
|
2016-01-28 |
2020-08-04 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
|
EP3481826B1
(en)
|
2016-07-08 |
2021-11-03 |
Rigel Pharmaceuticals, Inc. |
Tyrosine kinase inhibitors
|
|
ES2922379T3
(es)
*
|
2016-12-16 |
2022-09-14 |
Janssen Pharmaceutica Nv |
Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
|
|
JOP20190144A1
(ar)
|
2016-12-16 |
2019-06-16 |
Janssen Pharmaceutica Nv |
إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
|
|
WO2018117211A1
(ja)
*
|
2016-12-22 |
2018-06-28 |
参天製薬株式会社 |
眼疾患の治療及び／又は予防剤
|
|
UA122851C2
(uk)
|
2016-12-29 |
2021-01-06 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки піразолопіримідинів і способи їх застосування
|
|
DK3604304T3
(da)
|
2017-03-23 |
2022-10-31 |
Daegu Gyeongbuk Medical Innovation Found |
Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme
|
|
CN109535164B
(zh)
*
|
2017-09-21 |
2022-01-18 |
上海华汇拓医药科技有限公司 |
Jak激酶抑制剂及其制备方法和在医药领域的应用
|
|
GB201717260D0
(en)
*
|
2017-10-20 |
2017-12-06 |
Galapagos Nv |
Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
|
|
BR112020008850A2
(pt)
*
|
2017-11-03 |
2020-10-20 |
Aclaris Therapeutics, Inc. |
composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
|
|
US10800775B2
(en)
|
2017-11-03 |
2020-10-13 |
Aclaris Therapeutics, Inc. |
Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
DK3746429T3
(da)
|
2018-01-30 |
2022-05-02 |
Incyte Corp |
Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
|
|
CN112423759A
(zh)
|
2018-03-30 |
2021-02-26 |
因赛特公司 |
使用jak抑制剂治疗化脓性汗腺炎
|
|
TW202016110A
(zh)
|
2018-06-15 |
2020-05-01 |
比利時商健生藥品公司 |
Ｊａｋ激酶家族之小分子抑制劑
|
|
WO2020009946A1
(en)
|
2018-07-02 |
2020-01-09 |
Regents Of The University Of Minnesota |
Therapeutic compounds and methods of use thereof
|
|
CN119080779A
(zh)
|
2018-08-10 |
2024-12-06 |
阿克拉瑞斯治疗股份有限公司 |
吡咯并嘧啶itk抑制剂
|
|
WO2020081689A1
(en)
*
|
2018-10-16 |
2020-04-23 |
Dana-Farber Cancer Institute, Inc. |
Azaindole inhibitors of wild-type and mutant forms of lrrk2
|
|
US12240844B2
(en)
|
2019-01-18 |
2025-03-04 |
Voronoi, Inc. |
Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease
|
|
WO2020182159A1
(zh)
*
|
2019-03-14 |
2020-09-17 |
上海华汇拓医药科技有限公司 |
Jak激酶抑制剂及其制备方法和在医药领域的应用
|
|
AU2020265828A1
(en)
|
2019-05-02 |
2021-09-09 |
Aclaris Therapeutics, Inc. |
Substituted pyrrolopyridines as JAK inhibitors
|
|
KR102286372B1
(ko)
*
|
2019-05-27 |
2021-08-05 |
주식회사한국파마 |
Jak 저해제 화합물, 및 이를 포함하는 의약 조성물
|
|
CN112174951A
(zh)
*
|
2019-07-02 |
2021-01-05 |
深圳美莹基因科技有限公司 |
作为詹纳斯激酶1选择抑制剂的吡咯并[2，3-b]吡啶衍生物
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2021257863A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Pyrrolotriazine compounds as jak2 v617f inhibitors
|
|
WO2021257857A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Naphthyridinone compounds as jak2 v617f inhibitors
|
|
WO2022006457A1
(en)
|
2020-07-02 |
2022-01-06 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
|
WO2022046989A1
(en)
|
2020-08-27 |
2022-03-03 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
|
KR102551758B1
(ko)
*
|
2020-11-30 |
2023-07-05 |
주식회사한국파마 |
신규한 jak 특이 저해제 화합물, 및 이의 제조방법
|
|
KR20220081631A
(ko)
|
2020-12-09 |
2022-06-16 |
보로노이 주식회사 |
염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
|
|
US11919908B2
(en)
|
2020-12-21 |
2024-03-05 |
Incyte Corporation |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
|
|
WO2022182839A1
(en)
|
2021-02-25 |
2022-09-01 |
Incyte Corporation |
Spirocyclic lactams as jak2 v617f inhibitors
|
|
AU2022233254A1
(en)
|
2021-03-11 |
2023-10-26 |
Janssen Pharmaceutica Nv |
Lorpucitinib for use in the treatment of jak mediated disorders
|
|
JP2025509672A
(ja)
|
2022-03-17 |
2025-04-11 |
インサイト・コーポレイション |
Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物
|
|
WO2023208174A1
(zh)
*
|
2022-04-28 |
2023-11-02 |
杭州普济远成生物医药科技有限公司 |
去泛素化酶抑制剂及其应用
|
|
CN116283963A
(zh)
*
|
2022-12-05 |
2023-06-23 |
西安美莹基因科技有限公司 |
一种高效詹纳斯激酶1选择性抑制剂
|